CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy
VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company will host a live conference call and webcast with the investment community on Tuesday, March 25, 2014 at 1:30 p.m. PT to provide an update on the Company’s clinical development strategy for lead product candidate, PRO 140, including progress with its preparations for its treatment substitution Phase 2b study in patients with Human Immunodeficiency Virus (HIV). PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
Help employers find you! Check out all the jobs and post your resume.